Introduction {#H1-1-ZLD190008}
============

More than 1 000 000 total joint replacements (TJRs) are performed annually in the United States,^[@zld190008r1]^ most of which are for osteoarthritis.^[@zld190008r2]^ Diabetes is a frequent comorbidity in patients with osteoarthritis^[@zld190008r3]^ and suboptimal glucose control preoperatively is associated with poor TJR outcomes.^[@zld190008r4],[@zld190008r5]^ Despite the concern for hyperglycemia in the period before TJR, there is a paucity of data regarding the frequency of preoperative outpatient screening. We aimed to assess how frequently hemoglobin A~1c~ (HbA~1c~) was measured 90 days prior to TJR among Medicare enrollees.

Methods {#H1-2-ZLD190008}
=======

We conducted a cohort study using claims data from Medicare Parts A (hospital), B (medical), and D (pharmacy) from January 2010 to December 2014; data were analyzed from May 2018 to July 2019. The index date was the date of first TJR (total hip or knee) during the study period. Patients were aged 65 years or older and were continuously enrolled in Medicare for at least 360 days prior to the index date.

This study was approved by the Brigham and Women's Health institutional review board, which waived the requirement for obtaining patients' consent because data were deidentified and patients incurred minimal risk. We followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

*International Classification of Diseases, Ninth Revision, Clinical Modification*(*ICD-9-CM*) or *Current Procedural Terminology* codes were used to identify diabetes, complications of diabetes (nephropathy, neuropathy, retinopathy, or foot problems associated with diabetes), TJR, and comorbidities. Using claims from the 270 days prior to the 90-day outcome period, we created 4 mutually exclusive groups: (1) no diabetes (no *ICD-9* code for diabetes or diabetes complications and no claim for insulin or other antidiabetic medications); (2) diabetes and not receiving medication (≥1 *ICD-9* code for diabetes but no claim for insulin or other antidiabetic medications); (3) diabetes and receiving noninsulin medications for diabetes (≥1 *ICD-9* code for diabetes and ≥1 claim for noninsulin antidiabetic medications); and (4) diabetes and receiving insulin (≥1 *ICD-9* code for diabetes and ≥1 claim for insulin).

The primary outcome was the proportion of patients who had an HbA~1c~ level tested in the 90 days prior to TJR. We also assessed the proportion of patients who had a code for serum blood glucose level tested separately or in metabolic panels in the 90 days preceding TJR.

Results {#H1-3-ZLD190008}
=======

We had access to 1 046 660 claims for TJR; of these, 465 566 patients met the inclusion criteria ([Figure](#zld190008f1){ref-type="fig"}). Among the groups, mean age ranged from 73 to 75 years and 64% to 68% were female ([Table](#zld190008t1){ref-type="table"}). In the 90 days prior to TJR, 4.9% (95% CI, 4.8%-5.0%) of patients without diabetes had HbA~1c~ testing compared with 25.8% (95% CI, 25.4%-26.2%) of those with diabetes not receiving medication, 39.0% (95% CI, 38.6%-39.4%) of those with diabetes receiving noninsulin medications, and 43.4% (95% CI, 42.8%-44.1%) of those with diabetes receiving insulin. Serum glucose testing was performed in 37.2% (95% CI, 37.0%-37.4%) of those without diabetes, 45.7% (95% CI, 45.2%-46.1%) of those with diabetes not receiving medication, 47.7% (95% CI, 47.3%-48.1%) of those with diabetes receiving noninsulin medications, and 50.2% (95% CI, 49.5%-50.9%) of those with diabetes receiving insulin. The proportion of patients with HbA~1c~ or serum glucose level tested was 37.6% in those without diabetes, 48.6% in those with diabetes not receiving medication, 52.9% for those with diabetes receiving noninsulin medication, and 56.8% for those with diabetes receiving insulin.

![Cohort Selection Flow Diagram\
The criteria for exclusions were checked consecutively. *ICD-9* indicates *International Classification of Diseases, Ninth Revision*; TJR, total joint replacement.](jamanetwopen-2-e1910589-g001){#zld190008f1}

###### Baseline Characteristics of Study Cohort[^a^](#zld190008t1n1){ref-type="table-fn"}

  Characteristic                                               No. (%)                                    
  ------------------------------------------------------------ -------------- ------------- ------------- --------------
  Age, mean (SD), y                                            74 (6)         75 (6)        74 (6)        73 (6)
  No. of physician visits, median (IQR)                        7 (4-10)       9 (5-13)      8 (5-12)      10 (6-15)
  Total No. of unique prescription medications, median (IQR)   7 (4-10)       9 (6-13)      11 (8-14)     14 (11-18)
  Female                                                       229 306 (68)   33 031 (66)   37 957 (64)   13 126 (64)
  Race/ethnicity                                                                                          
  Black                                                        11 745 (4)     3313 (7)      4445 (8)      2036 (10)
  Hispanic                                                     3252 (1)       956 (2)       1482 (3)      516 (3)
  White                                                        312 919 (94)   43 942 (89)   51 431 (88)   17 328 (86)
  Other                                                        3516 (1)       1024 (2)      1343 (2)      365 (2)
  Missing                                                      3933 (1)       730 (1)       1004 (2)      286 (1)
  Complications of diabetes                                                                               
  Nephropathy                                                  NA             1521 (3)      3099 (5)      3000 (15)
  Neuropathy                                                   NA             4350 (9)      10 419 (18)   6896 (34)
  Retinopathy                                                  NA             1777 (4)      5908 (10)     5024 (25)
  Foot problems                                                NA             1564 (3)      1573 (3)      1233 (6)
  Treatment of diabetes                                                                                   
  Biguanide                                                    NA             NA            47 944 (80)   8405 (41)
  Sulfonylureas                                                NA             NA            18 082 (30)   3805 (19)
  Thiazolidinediones                                           NA             NA            7521 (13)     1436 (7)
  Glucagon-like peptide-1 receptor agonist                     NA             NA            1806 (3)      909 (4)
  Sodium-glucose cotransporter-2 inhibitors                    NA             NA            96 (0.2)      47 (0.2)
  Dipeptidyl peptidase-4 inhibitor                             NA             NA            9156 (15)     2395 (12)
  Insulin                                                      NA             NA            NA            20 531 (100)
  Other                                                        NA             NA            428 (1)       283 (1)
  Comorbidities                                                                                           
  Hypertension                                                 233 116 (70)   44 088 (88)   53 866 (90)   19 157 (93)
  Hyperlipidemia                                               209 826 (63)   41 425 (83)   49 901 (84)   17 489 (85)
  Coronary heart disease                                       15 403 (5)     4357 (9)      4354 (7)      2478 (12)
  Peripheral vascular disease                                  23 070 (7)     6917 (14)     6657 (11)     3651 (18)
  Obesity                                                      27 242 (8)     8221 (17)     10 716 (18)   5508 (27)
  History of stroke or transient ischemic attack               26 547 (8)     6369 (13)     6273 (11)     3003 (15)
  Chronic kidney disease                                       21 307 (6)     7179 (14)     7591 (13)     5891 (29)
  Atrial fibrillation                                          34 792 (10)    7407 (15)     6904 (12)     3192 (16)
  Congestive heart failure                                     18 422 (6)     6290 (13)     5672 (10)     4031 (20)

Abbreviations: IQR; interquartile range; NA, not applicable.

Baseline data were collected in the 270 days prior to the 90-day outcome period.

Discussion {#H1-4-ZLD190008}
==========

In this large Medicare cohort undergoing TJR, preoperative HbA~1c~ testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Prior research has shown that an elevated HbA~1c~ level is associated with postoperative complications and, furthermore, that screening and addressing risk factors such as HbA~1c~ preoperatively may reduce complications, highlighting the importance of HbA~1c~ screening.^[@zld190008r4],[@zld190008r5],[@zld190008r6]^

Limitations of our study include possible misclassification of diabetes, as we relied on *ICD-9* codes, although we also used medication dispensing data to maximize accuracy. We were unable to assess for screening with fingerstick blood glucose or inpatient testing. Data were available from 2010 to 2014 and may not reflect current practice.

In a real-world clinical setting, hyperglycemia is often not screened for prior to TJR. Further study on the utility of perioperative hyperglycemia monitoring and optimization is warranted.
